Context Therapeutics Inc. (NASDAQ:CNTX) ranks among the overlooked penny stocks to buy right now, supported by strong upside potential.
A sharp stock selloff tied to early clinical data has drawn a series of analysts defending the shares as oversold
The stock is down nearly 60% year-to-date. On June 16, 2026, Maxim analyst Jason McCarthy lowered the firm’s price target on Context Therapeutics Inc. (NASDAQ:CNTX) to $4 from $8 while maintaining a “Buy” rating. The cut followed the company’s interim Phase 1a data for CTIM-76 in platinum-resistant ovarian cancer, but McCarthy called the sharp negative stock reaction an overreaction, noting the study remains exploratory and focused on learning about the drug’s pharmacokinetic (PK) profile, dosing, safety, and initial efficacy.
That view echoed commentary from a day earlier. On June 15, 2026, Jones Research called the selloff in Context Therapeutics Inc. (NASDAQ:CNTX) a buying opportunity, describing the Phase I update of CTIM-76 in CLDN6-positive solid tumors as encouraging. The firm pointed to a 29% overall response rate in platinum-resistant ovarian cancer patients who had a median of seven prior therapies, contrasting that with Zymeworks’ ZW191, tested in patients with a median of three prior therapies.